Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature

Jairam Krishnamurthy, Devi Mukkai Krishnamurty, John J. Baker, Weining Zhen, Daniel Lydiatt, Apar Kishor Ganti

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Background: Salivary duct carcinoma (SDC) is a rare malignancy with a poor prognosis. Human epidermal growth factor receptor-2 (Her-2/neu) is overexpressed in SDC and, hence, HER-2/neu targeted therapy could be an option. Methods: A 72-year-old man presented with parotid swelling and cervical lymphadenopathy. He underwent a parotidectomy, modified radical neck dissection, and postoperative chemoradiation with cisplatin. A year later, he developed metastatic disease in the contralateral neck that was treated surgically with right axillary lymphadenopathy. He received radiation to both sites, concurrent with carboplatin. Two years later, he underwent resection of a lung metastasis. He then had progression in the axillary and mediastinal lymph nodes and received 5 cycles of docetaxel and trastuzumab followed by maintenance trastuzumab. Results: The patient had a partial response and restaging studies 9 months after therapy discontinuation did not show progression. Conclusion: Trastuzumab-based therapy is a potential therapeutic option for patients with SDC.

Original languageEnglish (US)
Pages (from-to)E372-E375
JournalHead and Neck
Issue number12
StatePublished - Dec 2013


  • HER-2/neu
  • chemotherapy
  • salivary duct carcinoma
  • survival
  • trastuzumab

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Salivary duct carcinoma responding to trastuzumab-based therapy: Case report and review of the literature'. Together they form a unique fingerprint.

Cite this